Aquestive Therapeutics’ (AQST) Market Outperform Rating Reiterated at JMP Securities

JMP Securities reissued their market outperform rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a research note released on Wednesday, Benzinga reports. They currently have a $9.00 target price on the stock.

A number of other research analysts have also recently commented on AQST. Leerink Partnrs upgraded Aquestive Therapeutics to a strong-buy rating in a research note on Friday, May 10th. Piper Sandler initiated coverage on Aquestive Therapeutics in a research note on Thursday, April 11th. They set an overweight rating and a $10.00 price objective on the stock. HC Wainwright reaffirmed a buy rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research report on Wednesday, June 5th. SVB Leerink began coverage on Aquestive Therapeutics in a report on Friday, May 10th. They issued an outperform rating and a $8.00 price objective for the company. Finally, Raymond James began coverage on Aquestive Therapeutics in a report on Thursday, March 28th. They issued an outperform rating and a $7.00 price objective for the company. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Aquestive Therapeutics currently has an average rating of Buy and an average price target of $7.83.

Aquestive Therapeutics Trading Up 0.4 %

Shares of AQST stock opened at $2.60 on Wednesday. The company has a market cap of $236.70 million, a PE ratio of -6.19 and a beta of 2.81. The company’s fifty day simple moving average is $3.09 and its 200-day simple moving average is $3.18. Aquestive Therapeutics has a 52 week low of $1.25 and a 52 week high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.08). The business had revenue of $12.05 million during the quarter, compared to the consensus estimate of $12.22 million. During the same quarter in the previous year, the business earned $0.11 earnings per share. Equities research analysts expect that Aquestive Therapeutics will post -0.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Aquestive Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new stake in Aquestive Therapeutics in the first quarter worth approximately $54,000. Lazard Asset Management LLC lifted its position in shares of Aquestive Therapeutics by 115.5% during the 1st quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock valued at $124,000 after acquiring an additional 15,601 shares during the last quarter. Jump Financial LLC acquired a new stake in shares of Aquestive Therapeutics during the 4th quarter valued at $60,000. PFG Investments LLC acquired a new stake in shares of Aquestive Therapeutics during the 1st quarter valued at $204,000. Finally, Virtu Financial LLC lifted its position in shares of Aquestive Therapeutics by 219.7% during the 1st quarter. Virtu Financial LLC now owns 102,836 shares of the company’s stock valued at $438,000 after acquiring an additional 70,666 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.